Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2022 06:00 ET | Source: MannKind

MannKind Corporation to Participate in the BTIG Biotechnology Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative...
June 03, 2022 10:00 ET | Source: MannKind

Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7

WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for...
May 24, 2022 06:00 ET | Source: MannKind

MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™

Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s Technosphere® inhalation technologyFirst approval of a dry powder inhaled treatment for PAH and PH-ILDManufacturing of Tyvaso...
May 19, 2022 06:00 ET | Source: MannKind

MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
May 17, 2022 06:06 ET | Source: MannKind

MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma

The once-daily insulin delivery device strengthens MannKind’s commitment to offering innovative mealtime diabetes solutions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE...
May 09, 2022 06:00 ET | Source: MannKind

MannKind Corporation Participating at Upcoming Conferences

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic...
May 05, 2022 16:00 ET | Source: MannKind

MannKind Corporation Reports 2022 First Quarter Financial Results

1Q 2022 Afrezza Net Revenue of $9.8 million; +21% vs. 1Q 20211Q 2022 Afrezza Gross Margin 77%; Gross Profit +99% vs 1Q 2021$233.0 million of Cash, Cash Equivalents, and Investments at March 31,...
April 28, 2022 06:00 ET | Source: MannKind

MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host...
April 27, 2022 06:05 ET | Source: MannKind

MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30

Simplified 2x dose of Technosphere® Insulin (TI) produced a statistically significant improvement in PPGE between Dose 1 & 2 from 45-120 minutesHigher dose of TI resulted in a mean difference of...
March 28, 2022 06:05 ET | Source: MannKind

MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference

DANBURY, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with...